TY - JOUR
AR - COR-2020-7-105
TI - Treating Acute Myeloid Leukemia in Patients Presenting with COVID-19
AU - Rutger , Callens
AU - Dieter , Stevens
AU - Sebastiaan , Dhont
AU - Elise , Peys
AU - Ine, Moors
JO - Clinical Oncology and Research
PY - 2020
DA - Sat 18, Jul 2020
SN - 2613-4942
DO - http://dx.doi.org/10.31487/j.COR.2020.07.05
UR - https://www.sciencerepository.org/treating-acute-myeloid-leukemia-in-patients-presenting-with-covid-19_COR-2020-7-105 
KW - acute myeloid leukemia, COVID-19, IDH1/2-inhibitors, FLT3-inhibitors, hypomethylating agents, treatment discontinuation
AB - Patients with hematological malignancies are at increased risk for severe COVID-19 with a high mortality
rate. In AML, more and more patients are treated on an outpatient basis. This gives rise to two dilemmas
in the face of COVID-19. The first one is whether to temporarily interrupt the oral antileukemia treatment
and the second one is which patients should be intubated. Here, we describe our institutional approach and
the underlying rationale in patients on lower intensity treatments for AML presenting with COVID-19